Shares of Stem, Inc. (NYSE:STEM – Get Free Report) have earned an average rating of “Hold” from the nine research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $1.90.
A number of research analysts have weighed in on the stock. Susquehanna lifted their price objective on shares of Stem from $0.50 to $0.60 and gave the company a “neutral” rating in a report on Wednesday, October 16th. UBS Group decreased their price objective on shares of Stem from $2.50 to $1.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. TD Cowen downgraded shares of Stem from a “buy” rating to a “hold” rating and cut their target price for the stock from $4.00 to $1.00 in a research note on Wednesday, August 7th. Evercore ISI dropped their price objective on shares of Stem from $9.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group dropped their target price on shares of Stem from $0.75 to $0.65 and set a “neutral” rating on the stock in a research report on Friday.
Read Our Latest Stock Report on Stem
Stem Stock Performance
Stem (NYSE:STEM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $34.00 million during the quarter, compared to the consensus estimate of $64.06 million. Stem had a negative net margin of 328.11% and a negative return on equity of 87.61%. The business’s revenue for the quarter was down 63.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.56) earnings per share. On average, sell-side analysts anticipate that Stem will post -0.52 EPS for the current fiscal year.
Institutional Trading of Stem
A number of institutional investors have recently added to or reduced their stakes in the stock. Rock Point Advisors LLC boosted its holdings in Stem by 7.3% during the second quarter. Rock Point Advisors LLC now owns 1,618,589 shares of the company’s stock worth $1,797,000 after buying an additional 109,810 shares in the last quarter. SIR Capital Management L.P. grew its holdings in Stem by 327.0% in the second quarter. SIR Capital Management L.P. now owns 1,578,575 shares of the company’s stock valued at $1,752,000 after purchasing an additional 1,208,875 shares during the period. Hsbc Holdings PLC grew its holdings in Stem by 7.4% in the second quarter. Hsbc Holdings PLC now owns 1,039,420 shares of the company’s stock valued at $1,133,000 after purchasing an additional 71,956 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Stem by 181.1% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 856,092 shares of the company’s stock worth $950,000 after buying an additional 551,492 shares during the period. Finally, AQR Capital Management LLC grew its stake in Stem by 5,770.4% during the second quarter. AQR Capital Management LLC now owns 777,648 shares of the company’s stock worth $863,000 after buying an additional 764,401 shares during the period. Hedge funds and other institutional investors own 61.63% of the company’s stock.
About Stem
Stem, Inc operates as a digitally connected, intelligent, and renewable energy storage network provider worldwide. The company offers energy storage hardware sourced from original equipment manufacturers (OEMs); edge hardware to aid in the collection of site data and real-time operation and control of the site and other optional equipment; and Athena, a software platform, which offers battery hardware and software-enabled services to operate the energy storage systems.
Featured Stories
- Five stocks we like better than Stem
- Airline Stocks – Top Airline Stocks to Buy Now
- Intel: Is Now the Time to Be Brave?Â
- How to Find Undervalued Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- The Most Important Warren Buffett Stock for Investors: His Own
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Stem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stem and related companies with MarketBeat.com's FREE daily email newsletter.